Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) has been assigned an average recommendation of “Hold” from the ten ratings firms that are currently covering the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $11.17.

Several equities research analysts recently commented on the stock. Leerink Swann reissued a “hold” rating on shares of Achillion Pharmaceuticals in a report on Sunday, June 12th. Jefferies Group reissued a “hold” rating on shares of Achillion Pharmaceuticals in a report on Tuesday, August 9th. FBR & Co assumed coverage on shares of Achillion Pharmaceuticals in a report on Thursday, September 15th. They issued an “outperform” rating and a $16.00 price target for the company. Robert W. Baird reissued an “outperform” rating and issued a $10.00 price target on shares of Achillion Pharmaceuticals in a report on Monday, June 6th. Finally, Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 17th.

Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 0.51% during trading on Tuesday, reaching $7.85. 1,167,029 shares of the company’s stock traded hands. The firm has a market capitalization of $1.07 billion, a PE ratio of 160.20 and a beta of 2.21. Achillion Pharmaceuticals has a one year low of $5.57 and a one year high of $10.95. The company has a 50-day moving average price of $8.52 and a 200 day moving average price of $8.40.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/achillion-pharmaceuticals-inc-nasdaqachn-receives-consensus-recommendation-of-hold-from-analysts.html

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01. During the same quarter in the previous year, the business posted ($0.25) earnings per share. On average, analysts anticipate that Achillion Pharmaceuticals will post ($0.62) earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. RTW Investments LLC boosted its position in shares of Achillion Pharmaceuticals by 31.1% in the first quarter. RTW Investments LLC now owns 2,558,859 shares of the biopharmaceutical company’s stock valued at $19,754,000 after buying an additional 606,937 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Achillion Pharmaceuticals by 5.7% in the second quarter. Vanguard Group Inc. now owns 8,454,713 shares of the biopharmaceutical company’s stock valued at $65,947,000 after buying an additional 455,251 shares during the last quarter. Bellevue Group AG purchased a new position in shares of Achillion Pharmaceuticals during the first quarter valued at $3,242,000. Emerald Acquisition Ltd. purchased a new position in shares of Achillion Pharmaceuticals during the second quarter valued at $1,393,000. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of Achillion Pharmaceuticals by 4.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 3,021,403 shares of the biopharmaceutical company’s stock valued at $23,567,000 after buying an additional 136,258 shares during the last quarter. 79.43% of the stock is currently owned by hedge funds and other institutional investors.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

5 Day Chart for NASDAQ:ACHN

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.